Markets
LEGOLAND Hosts "Red, White & BOOM!" Fireworks Show
Uncle Sam and Lady Liberty greet guests at LEGOLAND California on July 4, 2022 (Daniel Knighton/Getty Images)
rate check

Why investors will always be buying US bonds even as debt swells

Income, portfolio protection, and a pat on the back from regulators.

Karthik Sankaran
8/16/24 1:06PM

“Who will buy all the bonds?” 

You’ve probably heard this recently, usually around a government-deficit projection or debt-auction announcement.

The (rhetorical) question is grounded in three related concerns. One is the size of US government deficits and debt. Another is that deficits will push inflation above the coupon income earned from bonds. The third is that a government in cahoots with the Federal Reserve will hold rates down, risking (or welcoming) inflation in order to ease its debt burden. The jargon calls this last fiscal dominance, a practice that subjects unwitting holders of government debt to bondage.

And yet, the 10-year yield fell from 4.7% on April 25 to a closing low of about 3.8% on August 5. Much has happened since April, but this was mostly caused by rising anxiety about a precipitous slowdown that came to a head after weak July jobs data. This is interesting because one can expect two things in an economy with less activity: tax collections will fall, and expenditures (on unemployment benefits and such) will rise.

In other words, a weakening economy would result in rising debt-to-GDP ratios and the specter of insolvency that terrifies “whowillbuyers.” And when fears of a slowdown increase dramatically, yields on high-yield debt typically go higher. Junk gets junkier. By simultaneously raising the interest rate for refinancing debt and lowering revenue, a slowdown brings default closer. As that specter nears, any new buyer for debt must be compensated with higher yields — which only exacerbates solvency issues. But that did not happen to Treasuries.

Instead of fleeing from bonds, people fled into them. Ironically, one reason lies in what whowillbuyers complain about. The US government has a buyer in the Fed who could “print the money” the Treasury owes. Obviously this can go horribly wrong, as those invoking Weimar and Zimbabwe keep reminding us. But this also means the US government is not subject to a solvency constraint driven by vicious interactions between interest rates and growth, making it unlike any other debtor in the economy. This also applies to governments of other countries indebted in their own currencies and with a credible central bank. (For trick questions about Italy or Spain, see me after class.) For a US investor, this makes bonds a pretty safe place to be in most recessions most the time. And that’s exactly how they reacted.

There are other reasons to hold bonds. You get back at maturity all the money that you put in. Admittedly, it may buy you fewer things than when you bought the bonds, because of inflation, but even that varies. You would get less house than you did 10 years ago, but a lot more pixels and screen acreage. 

You would also likely have earned some income while you held it. Earning an income and receiving the par value of your principal might not seem like a big deal, but it helps. Ask a man who succumbed not once but twice in three decades to the siren call of fuel cells

Incentives for institutional investors are even stronger. Bonds are the most liquid securities in the world, making them preferred collateral. They are assigned a “zero-risk” weighting by regulators — i.e., banks don’t have to assign loss-absorbing capital to hold them. And, during the banking troubles last spring, the Fed created a program to lend money against bonds that valued them at face value rather than market price. 

So a bond pays you a predictable amount annually to hold it with a pretty cast-iron assurance that your principal will be returned (and comes without a deposit-insurance ceiling). You know that regulators dress it up with other enhancements for institutional buyers, and in many (but not all) instances of a slowing economy, its value will likely rise, acting as a dampener of portfolio volatility. What’s not to like?

BondProtection
60/40 US stock/bond portfolio and 10-year US Treasury yields

Here comes the fine print, but in regular size. The ability of a bond to offset other losses in a portfolio depends on two things. The first is its coupon (that is, the interest paid to investors), and the second is its maturity. The lower the coupon and the longer until the government returns your principal, the faster a bond’s value will plummet in the face of inflation. This makes sense — every year, you’re losing purchasing power. So that 0.85% coupon, 100-year Austrian bond issued in 2020? Yikes. But they’re not all like that.

There’s also a global consideration here. If inflation depends on the balance between supply and demand, then it matters what form economic shocks take. The 1970s saw OPEC oil shocks set off inflation in developed economies. Covid and Russia’s invasion of Ukraine were marked by a whiplash — a demand implosion that led to plummeting bond yields was followed by fiscal stimulus and serial supply shocks that pushed inflation higher, fast. One result: rising inflation and sluggish growth made low-coupon bonds drag down rather than buffer a “balanced” portfolio combining stocks and bonds. But if we return to something like the first two decades of the 2000s, where shocks were primarily to demand, bonds could perform that balancing function better.

I owe you some sense of what the term “high-coupon” might mean. My rule of thumb is that if you trust the Fed to do whats necessary to hit 2.0% inflation over the longer term, and the US economy grows at just under 2.0% real, a 4% coupon on a 10-year bond affords both income and a portfolio buffer against periodic cyclical hits to growth. Even if you don’t agree with the numbers, this exposition might help frame things. 

Perhaps then your answer to whowillbuyers will be: um, maybe me? 

Karthik Sankaran is a macro strategist/portfolio manager with 16 years experience on the buy side and sell side in emerging markets, foreign exchange, and interactions of national geopolitics with asset markets.

More Markets

See all Markets
markets

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.